HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

Podrobná bibliografie
Hlavní autoři:	Mafham, M, Preiss, D
Médium:	Journal article
Vydáno:	Elsevier 2018

Podobné jednotky

GLP-1 receptor agonists and cardiovascular outcome trials: An update
Autor: Eirini Andrikou, a další
Vydáno: (2019-11-01)

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Autor: Kristensen, SL, a další
Vydáno: (2019)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
Autor: Mustafa Kılıçkap, a další
Vydáno: (2021-02-01)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Autor: Fatemeh Taktaz, a další
Vydáno: (2024-07-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
Autor: Marta Seghieri, a další
Vydáno: (2018-11-01)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
Autor: Jinjing Wei, a další
Vydáno: (2022-12-01)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
Autor: María Isabel del Olmo-Garcia, a další
Vydáno: (2018-01-01)

Adverse effects of GLP – 1 Receptor Agonists
Autor: Anna Kasprzak, a další
Vydáno: (2025-02-01)

GLP-1 Receptor Agonists and Kidney Protection
Autor: Eulalia Valentina Greco, a další
Vydáno: (2019-05-01)

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Autor: Haran K, a další
Vydáno: (2024-11-01)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Autor: Xin Zhao, a další
Vydáno: (2021-08-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Autor: Qiyuan Keith Liu
Vydáno: (2024-07-01)

Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.
Autor: Qinghua Wang, a další
Vydáno: (2010-09-01)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
Autor: Collin Vandemark, a další
Vydáno: (2023-02-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
Autor: Lisa M Neff, a další
Vydáno: (2010-07-01)

Role and development of GLP-1 receptor agonists in the management of diabetes
Autor: Chee&nbsp;W Chia, a další
Vydáno: (2009-05-01)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
Autor: Ben Jones, a další
Vydáno: (2018-04-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Autor: Rizvi AA, a další
Vydáno: (2022-04-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
Autor: Daiji Kawanami, a další
Vydáno: (2020-06-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Autor: Miodrag Janić, a další
Vydáno: (2024-12-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
Autor: Joanna Wojda, a další
Vydáno: (2025-02-01)

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Autor: Sydney S. Wilbon, a další
Vydáno: (2023-12-01)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
Autor: Giulia Monti, a další
Vydáno: (2022-06-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
Autor: Neff LM
Vydáno: (2010-07-01)

GLP-1 receptor agonist as a modulator of innate immunity
Autor: Jun Chen, a další
Vydáno: (2022-12-01)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
Autor: Jiani Zhong, a další
Vydáno: (2024-05-01)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Autor: Francis S. Willard, a další
Vydáno: (2020-09-01)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Autor: Sara Piccini, a další
Vydáno: (2023-03-01)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
Autor: Gian Paolo Fadini, a další
Vydáno: (2020-04-01)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Autor: Daria Ja’arah, a další
Vydáno: (2021-10-01)

GLP-1 receptor agonists—another promising therapy for Alport syndrome?
Autor: Jan Boeckhaus, a další
Vydáno: (2025-03-01)

Advances in GLP-1 receptor agonists for pain treatment and their future potential
Autor: Yongtao He, a další
Vydáno: (2025-02-01)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
Autor: Aleksandra Jaroń, a další
Vydáno: (2024-08-01)

Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Autor: Hong Shurui
Vydáno: (2023-01-01)

A potentially serious adverse effect of GLP-1 receptor agonists
Autor: Jinmiao Lu, a další
Vydáno: (2023-05-01)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Autor: Haiyang Du, a další
Vydáno: (2022-11-01)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Autor: Jinmi Lee, a další
Vydáno: (2012-08-01)

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
Autor: Aurélie Pahud de Mortanges, a další
Vydáno: (2022-03-01)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
Autor: Karen Schneck, a další
Vydáno: (2024-03-01)

The benefits of GLP1 receptors in cardiovascular diseases
Autor: Lamija Ferhatbegović, a další
Vydáno: (2023-12-01)